## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 6.1% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($99.64)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. What to Expect From Revvityâ€™s Q4 2025 Earnings Report**
- Source: inkl | 20260105T100903 | Somewhat-Bearish | Relevance: 100%
- Revvity, Inc. (RVTY) is set to announce its Q4 2025 earnings, with analysts expecting an adjusted EPS of $1.54, an 8.5% increase from the previous year. Despite a robust earnings surprise history, the stock has underperformed the broader market, falling 12.4% over the past year due to weak constant-currency revenue growth and declining operating margins. Analysts maintain a "Moderate Buy" rating with a 16% upside potential, but caution remains due to a full valuation.

**2. Revvity introduces Signals Xynthetica, an AI-augmented design platform for molecular and materials discovery**
- Source: Scientific Computing World | 20260106T085933 | Bullish | Relevance: 100%
- Revvity has launched Signals Xynthetica, an AI-augmented design platform aimed at accelerating molecular and materials discovery. The platform integrates in-silico generation, predictive modeling, and experimental validation to connect AI models with real scientific workflows and data. This initiative seeks to transform molecular and materials design by leveraging artificial intelligence effectively.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +6.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 19.8x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.2B |
| Beta | 1.05 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 19.8 |
| Current P/E | 21.4 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.1% to 6.1% (+6.0% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (6.1% > 6.0%), caution on chasing. MRS_5 at 4.3% confirms short-term momentum alignment. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 6.14% (CS: 89) | Strong |
| RSI_14 | 67.0 | Neutral |
| MACD Histogram | 0.46 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 1.078x | Above |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $105.02
- **Stop Loss:** $99.64 (5.1% risk)
- **Target:** $110.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 245
- **Position Value:** $25,729.90
- **Portfolio %:** 25.73%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*